•The U.S. FDA approved a supplemental Biologics License Application (sBLA) for PALYNZIQ to include pediatric patients 12 years and older with Phenylketonuria (PKU).
•PALYNZIQ is the only enzyme substitution therapy approved for the treatment of people with PKU.
•The Phase 3 PEGASUS study showed statistically significant blood phenylalanine (Phe) lowering compared to diet alone.
•SEC Chairman Atkins is seeking to regain momentum in the crypto sector following what he described as a 'missed opportunity' under the previous administration.
•The statements signal a change in the commission's regulatory approach to be more open to digital assets.
